title: Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.
abstract: Recombinant modified vaccinia virus Ankara (MVA), encoding the measles virus (MV) fusion (F) and hemagglutinin (H) (MVA-FH) glycoproteins, was evaluated in an MV vaccination-challenge model with macaques. Animals were vaccinated twice in the absence or presence of passively transferred MV-neutralizing macaque antibodies and challenged 1 year later intratracheally with wild-type MV. After the second vaccination with MVA-FH, all the animals developed MV-neutralizing antibodies and MV-specific T-cell responses. Although MVA-FH was slightly less effective in inducing MV-neutralizing antibodies in the absence of passively transferred antibodies than the currently used live attenuated vaccine, it proved to be more effective in the presence of such antibodies. All vaccinated animals were effectively protected from the challenge infection. These data suggest that MVA-FH should be further tested as an alternative to the current vaccine for infants with maternally acquired MV-neutralizing antibodies and for adults with waning vaccine-induced immunity.
authors.affiliation: The Institute of Virology, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands.
authors.forename: K J
authors.initials: KJ
authors.lastname: Stittelaar
authors.forename: L S
authors.initials: LS
authors.lastname: Wyatt
authors.forename: R L
authors.initials: RL
authors.lastname: de Swart
authors.forename: H W
authors.initials: HW
authors.lastname: Vos
authors.forename: J
authors.initials: J
authors.lastname: Groen
authors.forename: G
authors.initials: G
authors.lastname: van Amerongen
authors.forename: R S
authors.initials: RS
authors.lastname: van Binnendijk
authors.forename: S
authors.initials: S
authors.lastname: Rozenblatt
authors.forename: B
authors.initials: B
authors.lastname: Moss
authors.forename: A D
authors.initials: AD
authors.lastname: Osterhaus
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors; D006389:Hemagglutinins, Viral / Q000235:genetics / Q000276:immunology*; D008252:Macaca fascicularis; D008457:Measles / Q000276:immunology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000276:immunology*; D008459:Measles virus / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus; D014760:Viral Fusion Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D008458:Measles Vaccine; D014614:Vaccines, Synthetic; D014760:Viral Fusion Proteins; C032397:hemagglutinin protein G, measles virus